-
公开(公告)号:EP4375277A1
公开(公告)日:2024-05-29
申请号:EP22845342.9
申请日:2022-07-20
发明人: LI, Yunfei , TAN, Liang , MO, Mingguang , ZHANG, Zhen , LIN, Xiaoyan , GU, Xiaowen , LI, Jiao
IPC分类号: C07D401/04 , C07D401/14 , A61K31/4439 , A61P1/16 , A61P3/00 , A61P9/00 , A61P11/00 , A61P13/00 , A61P25/00 , A61P27/00 , A61P35/00
CPC分类号: A61K31/4439 , A61P1/16 , A61P3/00 , A61P9/00 , A61P13/00 , A61P11/00 , A61P27/00 , A61P25/00 , A61P35/00 , C07D401/14 , C07D401/04
摘要: A triazolopyridine compound represented by formula I-a and a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as an LPA1 receptor inhibitor in the treatment of LPA1 related diseases.
-
公开(公告)号:EP4428129A1
公开(公告)日:2024-09-11
申请号:EP22889355.8
申请日:2022-11-03
发明人: TAN, Liang , DONG, Yuqiong , LIU, Min , LI, Jiao , LI, Jian , ZHANG, Zhen , LIN, Xiaoyan , LI, Yunfei
IPC分类号: C07D401/14 , A61K31/4025 , A61P9/00
CPC分类号: C07D401/14 , A61P9/00 , A61K31/4025
摘要: The disclosure provides a substituted phenylpropionic acid derivative and a use thereof. Specifically, the disclosure provides a compound as shown in formula II or a medicinal salt thereof, which can be used in the preparation of a drug for preventing and/or treating cardiovascular diseases.
-
3.
公开(公告)号:EP4289848A1
公开(公告)日:2023-12-13
申请号:EP22749078.6
申请日:2022-01-28
发明人: LI, Yunfei , LIU, Haomiao , ZOU, Hao , ZHANG, Zhen , PANG, Xiaming , GONG, Honglong , ZHANG, Chao , ZHANG, Fang
IPC分类号: C07D487/06 , C07D491/06 , C07D401/14 , C07D498/06 , A61K31/5383 , A61P35/00
摘要: Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formula I, wherein substituents are defined in the description. The fused tricyclic cyclin-dependent kinase inhibitor is used for preventing and/or treating cyclin-dependent kinase related diseases, in particular cancers.
-
公开(公告)号:EP4435104A1
公开(公告)日:2024-09-25
申请号:EP22894956.6
申请日:2022-11-18
发明人: LIN, Xiaoyan , LI, Yunfei , ZHANG, Zhen , DONG, Yuqiong , HOU, Zhe , ZHANG, Jianyu , GENG, Jun , MAO, Song , HUANG, Longfei , ZHOU, Yaqin , LV, Zhenzhen , HUANG, Yanfen , HUANG, Jinyu
IPC分类号: C12N15/113 , A61K31/713 , A61P9/12 , A61P9/10 , A61P13/12
CPC分类号: C12N15/113 , A61P9/12 , A61P9/10 , A61K31/713 , A61P13/12
摘要: An siRNA targeting angiotensinogen (AGT) and a pharmaceutical use of the siRNA. Specifically, the present invention relates to the siRNA targeting an AGT gene, an siRNA conjugate or a dsRNA, a composition, and a pharmaceutical use of the siRNA. The present invention also relates to a pharmaceutical composition, a cell or a kit comprising the siRNA, and a method for the siRNA to treat and/or prevent AGT-related disorders (such as hypertension).
-
公开(公告)号:EP4403555A1
公开(公告)日:2024-07-24
申请号:EP22869371.9
申请日:2022-09-16
发明人: LI, Yunfei , YU, Jian , ZHANG, Zhen , LIN, Xiaoyan , YANG, Yang , DING, Lin
IPC分类号: C07D471/04 , A61K31/4375 , A61P9/00 , A61P9/12
CPC分类号: A61P9/00 , A61P9/12 , A61K31/4375 , C07D471/04
摘要: The present disclosure relates to a substituted 1,4-dihydro-1,6-naphthyridine amide and a use thereof. Specifically, a compound represented by formula I or a pharmaceutically acceptable salt thereof is provided, where R1, R3-R11, Z1 and Z2 are as defined in the present disclosure.
-
公开(公告)号:EP4198034A1
公开(公告)日:2023-06-21
申请号:EP21855617.3
申请日:2021-08-13
发明人: LI, Wenming , LIU, Ning , LIU, Biao , LIU, Haomiao , YU, Jian , ZOU, Hao , ZHU, Wei , LI, Zhengtao , ZHANG, Zhen , LI, Yunfei
IPC分类号: C07D413/06 , A61K31/5377 , A61P13/00 , A61P25/04 , A61P11/14
摘要: The present disclosure relates to benzimidazole derivatives, a preparation method therefor and a medical use thereof. Specifically, the present disclosure relates to a benzimidazole derivative represented by the general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and its use as a therapeutic agent, in particular its use for the treatment of diseases related to P2X3 activity.
-
-
-
-
-